MARKET

CLYM

CLYM

Climb Bio
NASDAQ
1.730
-0.010
-0.57%
After Hours: 1.760 +0.03 +1.73% 19:52 12/04 EST
OPEN
1.730
PREV CLOSE
1.740
HIGH
1.770
LOW
1.710
VOLUME
257.56K
TURNOVER
--
52 WEEK HIGH
3.300
52 WEEK LOW
1.050
MARKET CAP
117.96M
P/E (TTM)
-2.3048
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CLYM last week (1124-1128)?
Weekly Report · 4d ago
Climb Bio reports inducement grant under Nasdaq listing rule
TipRanks · 11/25 12:16
Climb Bio Grants Stock Options to New Employee Under 2025 Inducement Plan
Reuters · 11/25 12:00
CLIMB BIO REPORTS INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 11/25 12:00
Press Release: Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Dow Jones · 11/25 12:00
Weekly Report: what happened at CLYM last week (1117-1121)?
Weekly Report · 11/24 09:51
Weekly Report: what happened at CLYM last week (1110-1114)?
Weekly Report · 11/17 09:51
Climb Bio, Inc. Reports Q3 2025 Financial Results
TipRanks · 11/11 04:26
More
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Webull offers Climb Bio Inc stock information, including NASDAQ: CLYM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLYM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLYM stock methods without spending real money on the virtual paper trading platform.